Ambit Biosciences Corp., of San Diego, withdrew its proposed initial public offering, stating that the current market was not "sufficiently attractive." Ambit filed its S-1 last year, hoping to raise $86 million to fund its portion of pivotal trials for quizartinib, being developed with partner Astellas Pharma Inc., of Tokyo, for acute myeloid leukemia.